Product Images Budesonide
View Photos of Packaging, Labels & Appearance
- 0.25mg-cartonlabel - 0.25mg cartonlabel
- 0.5mg-cartonlabel - 0.5mg cartonlabel
- figure-1 - figure 1
- figure-2 - figure 2
- figure-3 - figure 3
- foil-label-0.25mg2ml - foil label 0.25mg2ml
- foil-label-0.5mg2ml - foil label 0.5mg2ml
- ifu-fig-1 - ifu fig 1
- ifu-fig-2 - ifu fig 2
- ifu-fig-3 - ifu fig 3
- ifu-fig-4 - ifu fig 4
- nephron-logo - nephron logo
- structure - structure
Product Label Images
The following 13 images provide visual information about the product associated with Budesonide NDC 64980-638 by Rising Pharma Holdings, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
0.25mg-cartonlabel - 0.25mg cartonlabel
0.5mg-cartonlabel - 0.5mg cartonlabel
figure-1 - figure 1
This text provides an evaluation of a 12-week trial in pediatric patients who were not on inhaled corticosteroid therapy before the study. The trial measured the change in nighttime asthma symptoms from baseline over the course of the 12 weeks. Different dosages were tested, including 0.25 mg once daily, 0.5 mg once daily, and 1 mg once daily. The results show the changes in asthma symptoms at different time intervals and provide p-values for each dosage level.*
figure-2 - figure 2
This text shows data from a 12-week trial involving pediatric patients who were previously on inhaled corticosteroid therapy for asthma. The study evaluates nighttime asthma changes from baseline over different intervals of the 12-week period. The trial includes patients who were given either a placebo or doses of 0.25 mg or 0.5 mg twice daily. The p-values for the different doses are provided: 0.25 mg (p=0.022) and 0.5 mg (p=0.021).*
figure-3 - figure 3
A 12-week trial was conducted in pediatric patients who were either maintained on bronchodilators alone or inhaled corticosteroid therapy before the study entry. The study evaluated nighttime asthma changes from baseline over the 12-week period. Different dosages of inhaled corticosteroids were tested, including 0.25 mg once daily, 0.25 mg twice daily, 0.5 mg twice daily, and 1 mg once daily. The p-values for the different dosages were as follows: 0.25 mg once daily: 0.121, 0.25 mg twice daily: <0.001, 0.5 mg twice daily: 0.003, 1.0 mg once daily: 0.005.*
foil-label-0.25mg2ml - foil label 0.25mg2ml
This is a product description for a single-dose plastic ampule containing a suspension with miconized Budesonide. Each ampule delivers 2 mL of the suspension, with 0.5 mg of the active ingredient. It also contains various other ingredients. The instructions advise keeping it out of reach of children, not discarding the foil envelope until the last ampule is used, and shaking gently before use. It can be used with a jet nebulizer but not with an ultrasonic nebulizer. Storage recommendations include keeping it between 4-25°C, protecting from light, and using opened ampules within 2 weeks. Packaging includes 5x2mL ampules.*
foil-label-0.5mg2ml - foil label 0.5mg2ml
This text provides information about Lotexp, which is a Budesonide Inhalation Suspension medication. The package contains single-dose ampules each delivering 0.5 mg of micronized budesonide. It includes details on storage instructions, usage advice, and precautions. The text also mentions not to use in an ultrasonic nebulizer and to follow the patient instructions for proper use. Additionally, it mentions the manufacturer's information for customer service inquiries.*
ifu-fig-1 - ifu fig 1
ifu-fig-2 - ifu fig 2
ifu-fig-3 - ifu fig 3
ifu-fig-4 - ifu fig 4
nephron-logo - nephron logo
structure - structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
